Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
15.68B
Market cap15.68B
Price-Earnings ratio
22.37
Price-Earnings ratio22.37
Dividend yield
Dividend yield
Average volume
1.35M
Average volume1.35M
High today
$154.81
High today$154.81
Low today
$150.69
Low today$150.69
Open price
$151.62
Open price$151.62
Volume
604.30K
Volume604.30K
52 Week high
$186.12
52 Week high$186.12
52 Week low
$122.14
52 Week low$122.14

Stock Snapshot

Neurocrine(NBIX) stock is priced at $154.25, giving the company a market capitalization of 15.68B. It carries a P/E multiple of 22.37.

As of 2026-08-17, Neurocrine(NBIX) stock has fluctuated between $150.69 and $154.81. The current price stands at $154.25, placing the stock +2.4% above today's low and -0.4% off the high.

Neurocrine(NBIX) shares are trading with a volume of 604.3K, against a daily average of 1.35M.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

NBIX News

TipRanks 11h
Neurocrine price target lowered to $165 from $190 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Neurocrine (NBIX) to $165 from $190 and keeps a Hold rating on the shares. The firm believes the Vykat commerci...

Simply Wall St 2d
Can Neurocrine Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?

Earlier this month, Neurocrine Biosciences reported Phase 4 KINECT-PRO results showing once-daily INGREZZA improved patient-reported quality of life, functionin...

Can Neurocrine Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
Seeking Alpha 5d
Neurocrine slips as safety issues linked to Vykat XR resurface

Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added...

Neurocrine slips as safety issues linked to Vykat XR resurface

Analyst ratings

90%

of 30 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.